The CANTOS paper did not include subgroup analysis, but it is interesting to consider the possibility that certain patient populations may benefit from canakinumab more or less than others (e.g. smokers, diabetics, male vs female, etc). Which populations are likely to benefit most? Or do you believe benefit is best predicted only by extent of hs-CRP elevation? Why?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.